Federspiel J, Steinbichler T, Vorbach S, Eling M, Borena W, Seifarth C
Biomedicines. 2025; 13(2).
PMID: 40002772
PMC: 11852712.
DOI: 10.3390/biomedicines13020358.
Komitova K, Dimitrov L, Stancheva G, Kyurkchiyan S, Petkova V, Dimitrov S
Int J Mol Sci. 2025; 25(24.
PMID: 39769234
PMC: 11676902.
DOI: 10.3390/ijms252413468.
Daloiso A, Franz L, Mondello T, Tisato M, Negrisolo M, Zanatta P
Cancers (Basel). 2024; 16(22).
PMID: 39594842
PMC: 11592668.
DOI: 10.3390/cancers16223887.
Apeltrath C, Simon F, Riders A, Rudack C, Oberste M
Cancers (Basel). 2024; 16(22).
PMID: 39594750
PMC: 11593292.
DOI: 10.3390/cancers16223793.
Pawlicka M, Gumbarewicz E, Blaszczak E, Stepulak A
Cancers (Basel). 2024; 16(7).
PMID: 38611032
PMC: 11010970.
DOI: 10.3390/cancers16071354.
Aberrant Expression of Claudins in Head and Neck Carcinomas and Their Prognostic and Therapeutic Value: A Narrative Review.
Arabi T, Algheryafi L, Alodah N, Enabi H, Alshehry A, Ouban A
Cancers (Basel). 2023; 15(17).
PMID: 37686483
PMC: 10486703.
DOI: 10.3390/cancers15174208.
Interplay between Partial EMT and Cisplatin Resistance as the Drivers for Recurrence in HNSCC.
Ingruber J, Dudas J, Sprung S, Lungu B, Mungenast F
Biomedicines. 2022; 10(10).
PMID: 36289744
PMC: 9598677.
DOI: 10.3390/biomedicines10102482.
Epithelial-to-Mesenchymal Transition in Metastasis: Focus on Laryngeal Carcinoma.
Goulioumis A, Gyftopoulos K
Biomedicines. 2022; 10(9).
PMID: 36140250
PMC: 9496235.
DOI: 10.3390/biomedicines10092148.
Insights on possible interplay between epithelial-mesenchymal transition and T-type voltage gated calcium channels genes in metastatic breast carcinoma.
Ragab Ibrahim F, Naser Hussein Z, Yousef A, Abd El Moneim N, Hussein A, Ahmed A
Heliyon. 2022; 8(8):e10160.
PMID: 36060991
PMC: 9434037.
DOI: 10.1016/j.heliyon.2022.e10160.
Promising Biomarkers in Head and Neck Cancer: The Most Clinically Important miRNAs.
Thomaidou A, Batsaki P, Adamaki M, Goulielmaki M, Baxevanis C, Zoumpourlis V
Int J Mol Sci. 2022; 23(15).
PMID: 35897831
PMC: 9367895.
DOI: 10.3390/ijms23158257.
Expression of combined interference of slug and FoxC2 in endometrial carcinoma and its clinicopathological relationship.
Zhu Q, Tang M, Wu L
Transl Cancer Res. 2022; 9(9):5268-5280.
PMID: 35117893
PMC: 8797351.
DOI: 10.21037/tcr-20-809.
Foxhead box D1 promotes the partial epithelial-to-mesenchymal transition of laryngeal squamous cell carcinoma cells via transcriptionally activating the expression of zinc finger protein 532.
Fan L, Wang J, Deng P, Wang Y, Zhang A, Yang M
Bioengineered. 2022; 13(2):3057-3069.
PMID: 35112956
PMC: 8973586.
DOI: 10.1080/21655979.2021.2024978.
Placental-Cadherin, a biomarker for local immune status and poor prognosis among patients with tongue squamous cell carcinoma.
Wang H, Yu T, Mao L
Eur Arch Otorhinolaryngol. 2021; 279(7):3597-3609.
PMID: 34825969
DOI: 10.1007/s00405-021-07181-x.
Epithelial-to-Mesenchymal Transition-Derived Heterogeneity in Head and Neck Squamous Cell Carcinomas.
Baumeister P, Zhou J, Canis M, Gires O
Cancers (Basel). 2021; 13(21).
PMID: 34771518
PMC: 8582421.
DOI: 10.3390/cancers13215355.
Bile acids increase intestinal marker expression via the FXR/SNAI2/miR-1 axis in the stomach.
Wang N, Wu S, Zhao J, Chen M, Zeng J, Lu G
Cell Oncol (Dordr). 2021; 44(5):1119-1131.
PMID: 34510400
PMC: 8516775.
DOI: 10.1007/s13402-021-00622-z.
SLUG-related partial epithelial-to-mesenchymal transition is a transcriptomic prognosticator of head and neck cancer survival.
Schinke H, Pan M, Akyol M, Zhou J, Shi E, Kranz G
Mol Oncol. 2021; 16(2):347-367.
PMID: 34382739
PMC: 8763659.
DOI: 10.1002/1878-0261.13075.
Epithelial-to-Mesenchymal Transition and Neoangiogenesis in Laryngeal Squamous Cell Carcinoma.
Franz L, Nicole L, Frigo A, Ottaviano G, Gaudioso P, Saccardo T
Cancers (Basel). 2021; 13(13).
PMID: 34283055
PMC: 8267619.
DOI: 10.3390/cancers13133339.
Laryngeal Tumor Microenvironment.
Karpathiou G, Dumollard J, Peoch M
Adv Exp Med Biol. 2021; 1296:79-101.
PMID: 34185287
DOI: 10.1007/978-3-030-59038-3_5.
Identification of E2F transcription factor 7 as a novel potential biomarker for oral squamous cell carcinoma.
Zhou P, Xiao L, Xu X
Head Face Med. 2021; 17(1):7.
PMID: 33637098
PMC: 7908640.
DOI: 10.1186/s13005-021-00258-2.
A metalloproteinase of the disintegrin and metalloproteinases and the ThromboSpondin Motifs 6 as a novel marker for colon cancer: functional experiments.
Wang Y, Zhao Y, Kong X
Genet Mol Biol. 2020; 43(4):e20190266.
PMID: 33063817
PMC: 7564043.
DOI: 10.1590/1678-4685-GMB-2019-0266.